246 related articles for article (PubMed ID: 26835975)
41. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study.
Zahl PH; Gøtzsche PC; Mæhlen J
Lancet Oncol; 2011 Nov; 12(12):1118-24. PubMed ID: 21996169
[TBL] [Abstract][Full Text] [Related]
42. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
43. [Pathological characteristics in screening versus clinically-detected breast cancer].
Paziault M; Terrade FX; Fermeaux V; Pascal B; Darreye G; Dussartre C; Gilquin M; Labrousse F; Tubiana-Mathieu N
Bull Cancer; 2006 Jul; 93(7):731-6. PubMed ID: 16873082
[TBL] [Abstract][Full Text] [Related]
44. Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.
Chiarelli AM; Muradali D; Blackmore KM; Smith CR; Mirea L; Majpruz V; O'Malley FP; Quan ML; Holloway CM
Br J Cancer; 2017 May; 116(10):1254-1263. PubMed ID: 28359079
[TBL] [Abstract][Full Text] [Related]
45. Mammography screening study hampered by inadequate data.
Tabár L
BMJ; 2014 Nov; 349():g6823. PubMed ID: 25424720
[No Abstract] [Full Text] [Related]
46. Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality.
Barratt A
BMJ; 2015 Mar; 350():h867. PubMed ID: 25736426
[No Abstract] [Full Text] [Related]
47. Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.
Buist DS; Walker R; Bowles EJ; Carney PA; Taplin SH; Onega T; Kerlikowske K; Clinton W; Miglioretti DL
Cancer Epidemiol Biomarkers Prev; 2012 May; 21(5):720-7. PubMed ID: 22301831
[TBL] [Abstract][Full Text] [Related]
48. Surgeon-read screening mammography: an analysis of 11,948 examinations.
Apffelstaedt JP; Steenkamp V; Baatjes KJ
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():249-54. PubMed ID: 20853042
[TBL] [Abstract][Full Text] [Related]
49. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data.
Suhrke P; Mæhlen J; Schlichting E; Jørgensen KJ; Gøtzsche PC; Zahl PH
BMJ; 2011 Sep; 343():d4692. PubMed ID: 21914765
[TBL] [Abstract][Full Text] [Related]
50. Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer.
Helvie MA; Chang JT; Hendrick RE; Banerjee M
Cancer; 2014 Sep; 120(17):2649-56. PubMed ID: 24840597
[TBL] [Abstract][Full Text] [Related]
51. Comparing screening mammography for early breast cancer detection in Vermont and Norway.
Hofvind S; Vacek PM; Skelly J; Weaver DL; Geller BM
J Natl Cancer Inst; 2008 Aug; 100(15):1082-91. PubMed ID: 18664650
[TBL] [Abstract][Full Text] [Related]
52. Performance of digital screening mammography among older women in the United States.
Henderson LM; O'Meara ES; Braithwaite D; Onega T;
Cancer; 2015 May; 121(9):1379-86. PubMed ID: 25537958
[TBL] [Abstract][Full Text] [Related]
53. Emerging Trends in Family History of Breast Cancer and Associated Risk.
Shiyanbola OO; Arao RF; Miglioretti DL; Sprague BL; Hampton JM; Stout NK; Kerlikowske K; Braithwaite D; Buist DSM; Egan KM; Newcomb PA; Trentham-Dietz A
Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1753-1760. PubMed ID: 28986348
[No Abstract] [Full Text] [Related]
54. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
55. Performance measures among non-immigrants and immigrants attending BreastScreen Norway: a population-based screening programme.
Bhargava S; Akslen LA; Bukholm IRK; Hofvind S
Eur Radiol; 2019 Sep; 29(9):4833-4842. PubMed ID: 30762109
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG; Lacey JV; Carreon JD; Hoover RN
J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
[TBL] [Abstract][Full Text] [Related]
57. Persistent Untreated Screening-Detected Breast Cancer: An Argument Against Delaying Screening or Increasing the Interval Between Screenings.
Arleo EK; Monticciolo DL; Monsees B; McGinty G; Sickles EA
J Am Coll Radiol; 2017 Jul; 14(7):863-867. PubMed ID: 28457814
[TBL] [Abstract][Full Text] [Related]
58. In situ breast cancer: incidence trend and organised screening programmes in Italy.
Barchielli A; Federico M; De Lisi V; Bucchi L; Ferretti S; Paci E; Ponti A; Buiatti E
Eur J Cancer; 2005 May; 41(7):1045-50. PubMed ID: 15862754
[TBL] [Abstract][Full Text] [Related]
59. Optimizing Mammography Screening Intervals.
Yi M; Hunt KK
JAMA; 2015 Oct; 314(15):1635-6. PubMed ID: 26501538
[No Abstract] [Full Text] [Related]
60. Cumulative risk of cancer detection in breast cancer screening by protocol strategy.
Blanch J; Sala M; Román M; Ederra M; Salas D; Zubizarreta R; Sanchez M; Rué M; Castells X;
Breast Cancer Res Treat; 2013 Apr; 138(3):869-77. PubMed ID: 23471648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
